Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir

AIDS

Volumn 24, Issue 8, 2010, Pages 1223-1226

  Van Luin, Matthijs ^a,b   Van Der Ende, Marchina E ^c   Richter, Clemens ^b   Visser, Mirjam ^b   Faraj, Diari ^d   Van Der Ven, Andre ^a   Gelinck, Luc ^c,e   Kroon, Frank ^e   Wit, Ferdinand W ^f   Van Schaik, Ron Hn ^c   Kuks, Paul Fm ^b   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIJNSTATE HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; ATOVAQUONE PLUS PROGUANIL; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALARIA CONTROL; MULTICENTER STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TRAVEL; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ATOVAQUONE; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PROGUANIL; PYRIDINES; PYRIMIDINONES; RITONAVIR; YOUNG ADULT;

EID: 77951880233     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283389129     Document Type: Article

References (10)

1. FDA. Kaletra; summary of product characteristics. http://www. accessdata.fda.gov/drugsatfda-docs/label/2007/021226s022lbl. pdf. [Accessed 11 December 2009]
2. Dooley KE, Flexner C, Andrade AS. Drug interactions involving combination antiretroviral therapy and other antiinfective agents: repercussions for resource-limited countries. J Infect Dis 2008; 198:948-961.
3. Van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006; 80:159-168.
4. Iwamoto M, Wenning LA, Petry AS, Laethem M, De SM, Kost JT, et al. Minimal effects of ritonavir and efavirenz on the phar-macokinetics of raltegravir. Antimicrob Agents Chemother 2008; 52:4338-4343.
5. Burger DM, Huisman A, Van EN, Neisingh H, Van UP, Rongen GA, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenoty-pic probe. Clin Pharmacol Ther 2008; 84:698-703.
6. Lindegardh N, Blessborn D, Bergqvist Y. Simultaneous quanti-tation of the highly lipophilic atovaquone and hydrophilic strong basic proguanil and its metabolites using a new mixed-mode SPE approach and steep-gradient LC. J Chroma-togr Sci 2005; 43:259-266. (Pubitemid 40937573)
7. Waters LJ, Moyle G, Bonora S, D'Avolio A, Else L, Mandalia S, et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antiviral therapy 2007; 12:825-830. (Pubitemid 47235497)
8. Srivastava IK, Vaidya AB. A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob Agents Chemother 1999; 43:1334-1339. (Pubitemid 29259321)
9. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006; 42:52-60. (Pubitemid 43947946)
10. Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol 2008; 65:523-530. (Pubitemid 351365141)